Pfizer’s flood-damaged Gujarat cancer drug plant won’t resupply until 2028, deepening US chemotherapy shortages, ASHP said.
Astellas takes an option on Audax’s preclinical IL-12 drug DAX-044 for $285M upfront and option fees, plus up to $1.05B in ...
Scientists are the biggest converts in Endpoints Signal’s Q3 survey, with 78% of them now saying they expect AI to boost drug discovery within a year.
Plowshare Therapies, led by Kevin Strauss, aims to develop a gene therapy for maple syrup urine disease, targeting ...
Anthropic buys Mithril Medicine, a one-person stealth biotech backed by Atlas whose founder ran the “Professor Oak” account ...
The FDA’s approval for Celcuity’s cancer drug Revtorpyk on Tuesday was widely anticipated. What Wall Street didn’t expect was that the ...
Eli Lilly's Jacob Van Naarden leads aggressive dealmaking to offset tirzepatide's patent cliff, with 12+ acquisitions that ...
Researchers had been testing whether Artiva's off-the-shelf NK cell therapy called AB-101 could treat rheumatoid arthritis and other autoimmune diseases.
Q3 Biopharma Sentiment Index shows regulatory optimism rising after Marty Makary and Vinay Prasad's FDA exits, though scientists remain pessimistic.
Microsoft’s MAI-DxO diagnosed 83% of complex journal cases vs. 36% for doctors; a Beth Israel triage study starts within ...
BioNTech and DualityBio weigh next steps after HER2 ADC trastuzumab pamirtecan posts a modest Phase 3 win in HER2-low breast ...
Roche will seek European approval for its promising new breast cancer pill giredestrant later than it once expected, highlighting how US drug pricing pressure may be affecting pharmaceutical companies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results